Foundational patent application filed for TriCore

On November 14, 2025, a U.S. provisional patent application was filed seeking protection for the TriCore platform and its use in degrader-antibody conjugates. The filing is a foundational step in building the intellectual property supporting 3C Therapeutics’ development programs.